Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial-论文-万方医学网

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial

导出原文传递

翻译打印收藏纠错

作者： Vatche Tchekmedyian ^[1] ; Lara Dunn ^[2] ; Eric Sherman ^[3] ; Shrujal S. Baxi ^[4] ; Ravinder K. Grewal ^[5] ; Steven M. Larson ^[6] ; Keith S. Pentlow ; Sofia Haque ; R. Michael Tuttle ; Mona M. Sabra ; Stephanie Fish ; Laura Boucai ; Jamie Walters ; Ronald A. Ghossein ; Venkatraman E. Seshan ; Jeffrey A. Knauf ; David G. Pfister ; James A. Fagin ; Alan L. Ho

作者单位： Department of Radiology ^[1] Department of Medical Physics ^[2] Department of Medicine ^[3] Department of Pathology ^[4] Department of Epidemiology and Biostatistics ^[5] Department of Human Oncology and Pathogenesis Program ^[6]

关键词 BRAF mutant CDX-3379 radioiodine refractory thyroid cancer redifferentiation vemurafenib

发布时间 2022-07-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除